Rabia Gurses Ozden - Jul 7, 2023 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role: Chief Medical Officer
Signature: /s/ Donald Notman, Attorney-in-Fact for Rabia Gurses Ozden
Stock symbol: OCUL
Transactions as of: Jul 7, 2023
Transactions value $: -$4,102
Form type: 4
Date filed: 7/11/2023, 08:00 PM
Previous filing: Jun 13, 2023
Next filing: Feb 2, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCUL	Common Stock	Sale	-$4.1K	-832	-0.82%	$4.93	101K	Jul 7, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock sold pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on July 1, 2023. The sales do not represent a discretionary trade by the reporting person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.92 to $4.93, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Content

Represents shares of common stock sold pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on July 1, 2023. The sales do not represent a discretionary trade by the reporting person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.92 to $4.93, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.